Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E9.48 EPS (ttm)32.40 Insider Own0.10% Shs Outstand172.80M Perf Week0.86%
Market Cap50.99B Forward P/E9.42 EPS next Y32.59 Insider Trans-2.06% Shs Float165.01M Perf Month0.78%
Income5.88B PEG10.57 EPS next Q7.98 Inst Own89.60% Short Float2.53% Perf Quarter-0.42%
Sales14.42B P/S3.54 EPS this Y44.80% Inst Trans-4.73% Short Ratio2.06 Perf Half Y1.35%
Book/sh72.61 P/B4.23 EPS next Y-1.27% ROA22.00% Target Price318.07 Perf Year37.23%
Cash/sh23.25 P/C13.21 EPS next 5Y0.90% ROE44.50% 52W Range215.77 - 374.99 Perf YTD3.49%
Dividend- P/FCF7.70 EPS past 5Y20.50% ROI30.50% 52W High-18.11% Beta0.54
Dividend %- Quick Ratio1.50 Sales past 5Y8.20% Gross Margin87.50% 52W Low42.32% ATR9.69
Employees7400 Current Ratio1.70 Sales Q/Q1.30% Oper. Margin51.00% RSI (14)49.04 Volatility3.04% 2.96%
OptionableYes Debt/Eq0.48 EPS Q/Q13.00% Profit Margin40.80% Rel Volume0.94 Prev Close300.50
ShortableYes LT Debt/Eq0.36 EarningsApr 22 BMO Payout0.00% Avg Volume2.02M Price307.09
Recom2.70 SMA20-0.35% SMA50-0.14% SMA2008.05% Volume1,908,478 Change2.19%
Apr-23-20Downgrade Raymond James Mkt Perform → Underperform
Apr-23-20Downgrade Citigroup Neutral → Sell $365 → $240
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $389
Jan-27-20Upgrade Canaccord Genuity Hold → Buy $360
Dec-13-19Upgrade Credit Suisse Underperform → Neutral $260 → $300
Dec-02-19Downgrade Robert W. Baird Neutral → Underperform
Nov-12-19Initiated SunTrust Buy $337
Nov-01-19Downgrade Standpoint Research Buy → Hold
Oct-30-19Upgrade Bernstein Mkt Perform → Outperform
Oct-23-19Upgrade SVB Leerink Mkt Perform → Outperform $256 → $350
Oct-23-19Upgrade Guggenheim Neutral → Buy $256 → $365
Oct-23-19Reiterated H.C. Wainwright Buy $300 → $335
Oct-23-19Reiterated BofA/Merrill Underperform $200 → $235
Oct-17-19Resumed BofA/Merrill Underperform $200
Jun-28-19Downgrade Piper Jaffray Overweight → Neutral $280 → $250
Jun-05-19Upgrade Standpoint Research Hold → Buy
May-23-19Resumed Citigroup Neutral
May-23-19Initiated Wedbush Neutral
May-21-19Initiated Credit Suisse Underperform $198
May-29-20 08:47AM  Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates Zacks
08:00AM  Vir Biotechnology and Biogen Execute Agreement to Manufacture SARS-CoV-2 Antibodies for Potential COVID-19 Treatment GlobeNewswire
May-28-20 09:00AM  Is Biogen Stock A Buy Following An Unexpected Alzheimer's Drug Delay? Investor's Business Daily
07:30AM  Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science GlobeNewswire
May-26-20 12:55PM  Hedge Funds Are Betting On Biogen Inc. (BIIB) Insider Monkey
06:44AM  An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 24% Undervalued Simply Wall St.
05:37AM  Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store? Zacks
May-23-20 07:36AM  Better Buy: Biogen vs. Axsome Therapeutics Motley Fool
May-22-20 06:04PM  Richard Snow Buys Into Tyson and Reduces Dow in 1st Quarter GuruFocus.com
09:05AM  7 Top-Rated Biotech Stocks to Buy on the Hunt for a Vaccine InvestorPlace
06:07AM  Medtronic (MDT) Q4 Earnings Miss Estimates, Revenues Beat Zacks
May-21-20 02:49PM  Top Health Care Stocks for June 2020 Investopedia
May-20-20 09:23AM  Here are the hot dogs that hedge funds have used to outperform this year MarketWatch
08:58AM  Zacks.com featured highlights include: Graphic Packaging, Canadian Solar, Biogen and Vistra Energy Zacks
May-19-20 09:48AM  4 Low Price-to-Book Value Stocks to Buy in May Zacks
07:30AM  New Data at AAN Showcase Biogens Commitment to Advancing Innovation in MS GlobeNewswire
May-18-20 02:47PM  Moderna COVID-19 vaccine data is baby-step in right direction: Expert Yahoo Finance Video
07:30AM  New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients GlobeNewswire
May-15-20 10:18AM  STERIS' (STE) Q4 Earnings Surpass Estimates, Margins Rise Zacks
May-14-20 10:00AM  GNC Holdings' (GNC) Q1 Earnings and Sales Miss Estimates Zacks
09:34AM  AMN Healthcare (AMN) Q1 Earnings In Line With Estimates Zacks
09:28AM  Intersect ENT (XENT) Reports Wider-Than-Expected Q1 Loss Zacks
May-13-20 01:16PM  6 Stocks John Hussman Continues to Buy GuruFocus.com
10:09AM  Phibro (PAHC) Q3 Earnings Surpass Estimates, Margin Declines Zacks
10:05AM  HMS Holdings (HMSY) Earnings and Revenues Beat Estimates in Q1 Zacks
May-12-20 04:01PM  Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results GlobeNewswire
10:03AM  Allscripts (MDRX) Q1 Earnings and Revenues Miss Estimates Zacks
10:00AM  National Vision (EYE) Q1 Earnings Top Estimates, Margin Falls Zacks
May-11-20 05:40PM  US Indexes Post Some Gains Monday GuruFocus.com
11:58AM  Zimmer Biomet (ZBH) Q1 Earnings Top, Revenues Miss Estimates Zacks
10:26AM  Fresenius Medical (FMS) Q1 Earnings Miss Estimates, Fall Y/Y Zacks
10:07AM  Cardinal Health (CAH) Beats Q3 Earnings and Revenue Estimates Zacks
09:52AM  LHC Group (LHCG) Earnings and Revenues Beat Estimates in Q1 Zacks
May-08-20 10:33AM  OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates Zacks
08:59AM  Avanos Medical (AVNS) Q1 Earnings Lag Estimates, Revenues Top Zacks
08:51AM  DENTSPLY SIRONA (XRAY) Posts Weak Q1 Preliminary Results Zacks
08:50AM  Integra (IART) Lags Q1 Earnings Estimates, Withdraws Outlook Zacks
08:50AM  Glaukos (GKOS) Q1 Earnings and Revenues Miss Estimates Zacks
07:57AM  Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates Zacks
May-07-20 03:28PM  Nasdaq Stock Exchange president on IPO outlook amid COVID-19 Yahoo Finance Video
11:03AM  Amedisys (AMED) Q1 Earnings Beat, Operating Margin Falls Zacks
10:40AM  QIAGEN (QGEN) Q1 Earnings Lag Estimates, Operating Margin Up Zacks
10:33AM  AmerisourceBergen (ABC) Q2 Earnings & Revenues Top Estimates Zacks
09:14AM  Nevro (NVRO) Earnings and Revenues Beat Estimates in Q1 Zacks
09:09AM  Becton Dickinson (BDX) Q2 Earnings and Revenues Top Estimates Zacks
May-06-20 11:48AM  CVS Health (CVS) Q1 Earnings Top Estimates, Costs Escalate Zacks
11:33AM  Haemonetics (HAE) Q4 Earnings Lag Estimates, Margins Expand Zacks
10:51AM  Inogen's (INGN) Q1 Earnings and Revenues Beat Estimates Zacks
10:49AM  DaVita (DVA) Earnings and Revenues Beat Estimates in Q1 Zacks
10:23AM  PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates Zacks
May-05-20 03:26PM  Coronavirus U.S. death toll may hit 134k+ by early August, study reveals Yahoo Finance Video
03:11PM  Stocks surge as more states move to reopen amid coronavirus Yahoo Finance Video
11:21AM  Henry Schein (HSIC) Q1 Earnings and Revenues Top Estimates Zacks
May-04-20 07:57PM  Apple borrows on the cheap to fund buybacks, dividends Reuters
05:59PM  Cytokinetics Trading at Half High Target of $30 GuruFocus.com
03:12PM  Trump expresses confidence for coronavirus vaccine by the end of the year Yahoo Finance Video
10:55AM  Hill-Rom's (HRC) Q2 Earnings Top Estimates, Margins Expand Zacks
10:38AM  Why Biogen Shares Fell 6.18% in April Motley Fool
10:26AM  Syneos Health (SYNH) Tops Q1 Earnings Estimates, Margins Down Zacks
May-01-20 06:55AM  Has Biogen Found the Answer to Treating Alzheimer's? Motley Fool
Apr-30-20 03:08PM  Gilead's remdesivir will set new standard of care for coronavirus treatment: Fauci Yahoo Finance Video
Apr-28-20 11:16AM  Axsome Shares Jump 25% on Alzheimer's Study Results GuruFocus.com
10:28AM  Will Strong HIV Sales Drive Gilead's (GILD) Q1 Earnings? Zacks
08:51AM  The Zacks Analyst Blog Highlights: Intel, Novartis, Toyota Motor, Union Pacific and Biogen Zacks
Apr-27-20 05:52PM  The Latest Updates on 9 Experimental Coronavirus Treatments Barrons.com
04:06PM  Biogen Prices $3.0 Billion of Senior Unsecured Notes GlobeNewswire
01:05PM  Top Research Reports for Intel, Novartis & Toyota Zacks
09:53AM  Biogen Inc. -- Moody's rates Biogen's notes Baa1; stable outlook Moody's
Apr-26-20 08:26AM  Biogen Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions Simply Wall St.
Apr-24-20 10:19AM  Edited Transcript of BIIB earnings conference call or presentation 22-Apr-20 12:00pm GMT Thomson Reuters StreetEvents
06:00AM  Sangamo- Early-Stage Progress in Gene Therapy MoneyShow
Apr-23-20 05:50PM  Were Hedge Funds Right About Biogen Inc. (BIIB)? Insider Monkey
03:49PM  Some Biogen Analysts Unimpressed By Explanation For Aducanumab Filing Delay Benzinga
03:26PM  21% tested positive for coronavirus antibodies in NYC, Cuomo says Yahoo Finance Video
01:55PM  'We're going to be in a lot of trouble' if we roll back coronavirus restrictions: Johns Hopkins doctor Yahoo Finance
10:47AM  Biogen Stock Drops as Analysts Lose Faith in Experimental Alzheimers Drug Barrons.com
03:02AM  Japanese shares snap 3-day losing streak as battered stocks bought back Reuters
Apr-22-20 11:24PM  Japanese shares rise after 3 days of falls; Eisai slumps on drug delay Reuters -9.42%
06:26PM  US Indexes Close Higher Wednesday GuruFocus.com
04:32PM  Biogen Says 'Unusual' Circumstances Led To Alzheimer's Delay; Shares Dive Investor's Business Daily
03:36PM  How the $484B stimulus bill will impact the healthcare sector Yahoo Finance Video
10:23AM  Biogen Delays Regulatory Filing For Approval Of Alzheimer's Drug, Shares Slump Benzinga
10:20AM  Biogen delays 'complex and unpredecented' Alzheimers drug application American City Business Journals
09:50AM  Dow rebounds more than 400 points as Congress looks to roll out new stimulus package MarketWatch
09:28AM  Biogen (BIIB) Stock Down Despite Q1 Earnings & Sales Beat Zacks
09:26AM  Recap: Biogen Q1 Earnings Benzinga
09:20AM  Biogen Earnings Top Forecasts, but the Stock Is Falling on Its Alzheimers-Drug Delay Barrons.com
09:07AM  Biogen Announces 1Q20 Beat, But Aducanumab Update Steals The Show SmarterAnalyst
08:32AM  Biogen Reports Better-Than-Expected Earnings - Stock Lower TheStreet.com
08:03AM  Biogen's stock falls 6% though earnings beat expectations MarketWatch
07:13AM  Biogen posts marginal rise in first-quarter sales Reuters
06:21AM  Do You Know What Biogen Inc.'s (NASDAQ:BIIB) P/E Ratio Means? Simply Wall St.
06:00AM  Biogen, Inc. to Host Earnings Call ACCESSWIRE
Apr-21-20 07:36PM  Delta, AT&T earnings: What to know in markets Wednesday Yahoo Finance
04:37PM  Biogen CEO nabs highest-ever paycheck during rollercoaster year American City Business Journals
Apr-20-20 05:45PM  Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics GlobeNewswire
10:09AM  Biogen (BIIB) to Report Q1 Earnings: What's in the Cards? Zacks
Apr-19-20 11:28AM  Coronavirus, Netflix earnings, economic data: What to know in the week ahead Yahoo Finance
Apr-16-20 06:50PM  5 Pharmaceutical Companies to Consider as Coronavirus Vaccine Race Heats Up GuruFocus.com
07:51AM  Biogen joins consortium for building COVID-19 'biobank' Reuters
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHERWIN STEPHEN ADirectorMar 11Option Exercise58.4612,278717,77216,517Mar 12 06:56 PM
SHERWIN STEPHEN ADirectorMar 11Sale295.222,434718,57414,353Mar 12 06:56 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.004,847033,775Feb 19 06:20 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 15Option Exercise0.001,213015,019Feb 19 06:17 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.0044102,672Feb 19 06:13 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 15Option Exercise0.001,553037,261Feb 19 06:09 PM
Kramer RobinVP, Chief Accounting OfficerFeb 12Option Exercise0.001320282Feb 14 06:37 PM
Karp DanielEVP, Corporate DevelopmentFeb 12Option Exercise0.0096001,224Feb 14 06:36 PM
Guindo ChirfiEVP Glob. Prod Strat and CommFeb 12Option Exercise0.001,68004,375Feb 14 06:34 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.003,54705,021Feb 14 06:32 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.001,15402,337Feb 14 06:30 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerFeb 12Option Exercise0.001,91903,732Feb 14 06:27 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.005,967036,389Feb 14 06:25 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.0011,994031,483Feb 14 06:19 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 12Option Exercise0.005,216014,509Feb 14 06:16 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,30202,219Jan 06 04:14 PM
Kramer RobinVP, Chief Accounting OfficerDec 03Option Exercise0.00840175Dec 05 04:24 PM
Posner Brian SDirectorDec 02Sale292.351,055308,4296,995Dec 03 05:58 PM
Guindo ChirfiEVP Glob. Prod Strat and CommDec 01Option Exercise0.0054302,855Dec 03 05:59 PM
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0017902,295Aug 05 04:20 PM
Karp DanielEVP, Corporate DevelopmentJul 02Option Exercise0.001960322Jul 05 04:51 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,12608,525Jun 04 04:56 PM